Tclin PDE4B cAMP-specific 3',5'-cyclic phosphodiesterase 4B

Protein Summary

Description

Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents. This gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family. The encoded protein regulates the cellular concentrations of cyclic nucleotides and thereby play a role in signal transduction. Altered activity of this protein has been associated with schizophrenia and bipolar affective disorder. Alternative splicing and the use of alternative promoters results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2014]

Uniprot Accession IDs

• Q07343
• A5YW33
• O15443
• Q13945
• Q5TEK4
• Q5TEK5
• Q5TEK6

Gene Name

• PDE4B

Ensembl ID

• ENST00000329654
• ENSP00000332116
• ENSG00000184588
• ENST00000341517
• ENSP00000342637
• ENST00000371045
• ENSP00000360084
• ENST00000423207
• ENSP00000392947
• ENST00000480109
• ENSP00000432592

Symbol

• DPDE4
• DPDE4
• PDEIVB

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
trait	1
biological process	0.95
drug	0.92
molecular function	0.91
PubMedID	0.89

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 221.36   (req: < 5)

Gene RIFs: 56   (req: <= 3)

Antibodies: 445   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 221.36   (req: >= 5)

Gene RIFs: 56   (req: > 3)

Antibodies: 445   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 19

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 1114

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drugs: 9